Loading clinical trials...
Loading clinical trials...
This is a staggered randomised controlled trial that aims to assess the impact of an automated insulin delivery (AID) system on glucose, gastrointestinal and patient-reported outcomes.
Following a run-in period of 2 weeks, participants will be randomised to control or hybrid automated insulin delivery (AID) using the 780G system and will remain in the intervention phase of the study for 12 weeks (4-week control, then 4-week AID or Control and finally 4-week AID). The total duration for each participant will be 14 weeks. There are 5 study visits (combination of face to face or/and remote) and two telephone visits in total.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Imperial College London and Imperial College Healthcare NHS Trust
London, United Kingdom
Start Date
August 16, 2023
Primary Completion Date
June 30, 2024
Completion Date
June 30, 2024
Last Updated
September 13, 2023
16
ESTIMATED participants
Hybrid Automated Insulin Delivery
DEVICE
Lead Sponsor
Imperial College London
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03876288